- Non-24-Hour Sleep-Wake Disorder (Non-24) is primarily seen in totally blind individuals with no light perception, disrupting their circadian rhythms. The market is growing due to increased healthcare focus on sleep health, FDA approvals of targeted therapies, and patient advocacy efforts improving diagnosis rates
- The demand for these microscopes is significantly driven by the increasing prevalence of age-related eye conditions and advancements in surgical techniques
- North America is expected to dominate the Non-24-Hour Sleep-Wake Disorder Drugs market due to strong clinical infrastructure and availability of drugs like tasimelteon, while developing markets are expanding awareness through neurology and sleep medicine networks
- Asia-Pacific is expected to be the fastest growing region in the Non-24-Hour Sleep-Wake Disorder Drug market during the forecast period due to increasing awareness of sleep disorders and advancements in healthcare infrastructure.
- Melatonin agonists are expected to dominate due to their targeted mechanism of action and minimal side effect profiles
